当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2019年第10期
编号:13344790
基于血清Betatrophin水平的非酒精性脂肪肝列线图预测模型的建立与分析(4)
http://www.100md.com 2019年4月5日 《中国医药导报》 2019年第10期
     [4] European Association for the Study of the Liver,European Association for the Study of Diabetes(EASD. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease [J]. Obesity Facts,2016,9(2):65-90.

    [5] Ballestri S,Romagnoli D,Nascimbeni F,et al. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications[J]. Expert Rev Gastroent,2015,9(5):603-627.

    [6] Chen X,Lu P,He W,et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance [J]. J Clin Endocr Metab,2015, 100(1):E96-E100.

    [7] Lee Y,Lee SG,Lee CJ,et al. Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease:animal and human studies [J]. Sci Rep,2016,6(6):24 013.

    [8] 劉捷,王永红,罗蓉,等.ZJU指数筛查对健康体检人群非酒精性脂肪肝患病风险预测的价值评估:一项基于重庆市体检人群的单中心研究[J].重庆医科大学学报,2017,42(2):244-248.

    [9] 王景骅,虞朝辉.非酒精性脂肪性肝病的诊断研究进展[J].中华肝脏病杂志,2017,25(2):115-118.

    [10] 夏明锋,高鑫.无创定量肝脏脂肪含量的新方法[J].中华内分泌代谢杂志,2012,28(8):611-613., http://www.100md.com(高福来 谢长顺 张利利)
上一页1 2 3 4